RGD Reference Report - The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Authors: Colaizzo, D  Amitrano, L  Tiscia, GL  Scenna, G  Grandone, E  Guardascione, MA  Brancaccio, V  Margaglione, M 
Citation: Colaizzo D, etal., J Thromb Haemost. 2007 Jan;5(1):55-61. Epub 2006 Oct 20.
RGD ID: 10449391
Pubmed: (View Article at PubMed) PMID:17059429
DOI: Full-text: DOI:10.1111/j.1538-7836.2006.02277.x

BACKGROUND: Myeloproliferative disorders (MPDs) represent a risk factor for thrombosis in the portal, mesenteric, and hepatic districts. OBJECTIVE: We aimed to assess whether the Janus kinase 2 (JAK2) V617F mutation, an acquired mutation that occurs in MPD patients, is a risk factor for portal and mesenteric venous thrombosis (PMVT) independently of the presence of overt MPDs. PATIENTS AND METHODS: The medical histories of 99 patients presenting with PMVT were obtained. The presence of the JAK2 V617F and VHL 598C > T mutations was determined by polymerase chain reaction followed by restriction enzyme analysis and direct cycle sequence analysis. RESULTS: Over a 10-year period of observation, of the 99 patients presenting with PMVT, the JAK2 V617F mutation was detected in heterozygous state in 17 individuals [17.2%; 95% confidence interval (95% CI) 10.9-25.9]. None of the patients presenting with the JAK2 V617F mutation carried an inherited thrombophilic risk factor. Seven patients with (43.8%; 95% CI 19.8-70.1) and two without (2.4%; 95% CI 0.3-8.4) the JAK2 V617F mutation had a diagnosis of MPD at the occurrence of the venous thrombotic event. After a median follow-up of 41 months (range 3-114 months), three out of the 10 patients carrying the JAK2 V617F mutation were then diagnosed as having idiopathic myelofibrosis (n = 2) or polycythemia vera (n = 1), whereas in seven patients a MPD was not detected. Two of the 83 patients without the JAK2 V617F mutation went on to develop MPDs. CONCLUSIONS: Determination of the JAK2 V617F mutation may contribute to the search for genetic determinants of PMVT and may be useful to recognize patients who should be carefully observed for the subsequent development of overt MPDs.


Disease Annotations    
Venous Thrombosis  (IAGP,ISO)

Objects Annotated

Genes (Rattus norvegicus)
Jak2  (Janus kinase 2)

Genes (Mus musculus)
Jak2  (Janus kinase 2)

Genes (Homo sapiens)
JAK2  (Janus kinase 2)

Additional Information